The Flow Cytometry Core Facility (FCCF) at the Moffitt Cancer Center was established in 1990 to provide a centralized flow cytometry service for Cancer Center members. Flow cytometry is an indispensable analytical tool for cell biology, immunology and translational research efforts at the Cancer Center. This technology provides a means for rapidly and accurately analyzing multiple characteristics of biological particles, as well as an ability to rapidly isolate and purify cell populations of interest for the purpose of assessing immunological functions and molecular distinctions, cell culture cloning and animal transplantation studies. The FCCF is staffed with highly trained instrument specialists with a combined 36 years of research-based flow cytometry experience. The facility houses six bench-top analyzers, two cell sorters, a bead array analyzer, an automated bead sorter and a fluorescent microscope. This includes the most recently added BD Biosciences customized LSR II analyzer, which was added in response to increased demand for sophisticated polychromatic analyses and high throughput capability. Its customized optical bench has expanded services to the Moffitt investigators doing novel, cutting-edge cancer biology studies. Fifty-six funded members routinely access the FCCF, which is up from thirty-nine in the 2006 review period. In 2008, the FCCF began to use the Laboratory Information Management System (LIMS) to consolidate usage tracking, scheduling, and billing. Flow LIMS also provides a secure repository for Core project data that is accessible by the Pl and the laboratory staff. The FCCF provides critical support for the scientific programs at the Cancer Center by providing investigators with access to state-of-the-art instrumentation, cutting-edge cytometry applications and an exceptionally well trained staff. Overall usage in the FCCF has increased over 30% since the 2006 CCSG submission. The Core requests CCSG Support of $57,049, which is 24% of its operational budget. Over 93% of usage is by Moffitt members and peer-reviewed.

Public Health Relevance

The FCCF provides Moffitt Members a high-quality, state-of-the-art facility that has consistently met investigators'demands for flow cytometry. The core provides researchers with a well-managed, cost-effective facility that functions as a repository for centralized technical expertise, sophisticated instrumentation and software, as well as educational and training opportunities.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
H. Lee Moffitt Cancer Center & Research Institute
United States
Zip Code
Chung, Brile; Stuge, Tor B; Murad, John P et al. (2014) Antigen-specific inhibition of high-avidity T cell target lysis by low-avidity T cells via trogocytosis. Cell Rep 8:871-82
Charbonneau, Bridget; Block, Matthew S; Bamlet, William R et al. (2014) Risk of ovarian cancer and the NF-*B pathway: genetic association with IL1A and TNFSF10. Cancer Res 74:852-61
Unrod, Marina; Simmons, Vani N; Sutton, Steven K et al. (2014) A randomized clinical trial of self-help intervention for smoking cessation: research design, interventions, and baseline data. Contemp Clin Trials 38:284-90
Osorio, Ana; Milne, Roger L; Kuchenbaecker, Karoline et al. (2014) DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. PLoS Genet 10:e1004256
Padron, Eric; Yoder, Sean; Kunigal, Sateesh et al. (2014) ETV6 and signaling gene mutations are associated with secondary transformation of myelodysplastic syndromes to chronic myelomonocytic leukemia. Blood 123:3675-7
Hampras, Shalaka S; Viscidi, Raphael P; Helzlsouer, Kathy J et al. (2014) Prospective study of seroreactivity to JC virus T-antigen and risk of colorectal cancers and adenomas. Cancer Epidemiol Biomarkers Prev 23:2591-6
Chen, Ning; Chon, Hye Sook; Xiong, Yin et al. (2014) Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel. Oncol Rep 31:376-83
Molife, L Rhoda; Yan, Li; Vitfell-Rasmussen, Joanna et al. (2014) Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors. J Hematol Oncol 7:1
Carvalho, Renato S; Fernandes, Vanessa C; Nepomuceno, Thales C et al. (2014) Characterization of LGALS3 (galectin-3) as a player in DNA damage response. Cancer Biol Ther 15:840-50
Rizwani, Wasia; Schaal, Courtney; Kunigal, Sateesh et al. (2014) Mammalian lysine histone demethylase KDM2A regulates E2F1-mediated gene transcription in breast cancer cells. PLoS One 9:e100888

Showing the most recent 10 out of 108 publications